1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018, 68(6):394–424.
2.Durrani S, Heena H: Controversies Regarding Ovarian Suppression and Infertility in Early Stage Breast Cancer. Cancer management and research 2020, 12:813–817.
3.Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A: Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 2020, 395(10226):817–827.
4.Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, Halberg F, Hoffman K, Horst K, Moran J et al: Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Practical radiation oncology 2018, 8(3):145–152.
5.Mastectomy Decisions Audit Collaborative obotWMRC: Multicentre prospective observational study evaluating recommendations for mastectomy by multidisciplinary teams. The British journal of surgery 2020, 107(3):227–237.
6.Jasra S, Anampa J: Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review. Current treatment options in oncology 2018, 19(6):30.
7.Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK et al: Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2005, 23(6):1169–1177.
8.Gomez-Miragaya J, Moran S, Calleja-Cervantes ME, Collado-Sole A, Pare L, Gomez A, Serra V, Dobrolecki LE, Lewis MT, Diaz-Lagares A et al: The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. Molecular cancer research: MCR 2019, 17(10):2063–2076.
9.Gomez-Miragaya J, Diaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B et al: Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer research 2019, 79(16):4258–4270.
10.Fakih M, Ouyang C, Wang C, Tu TY, Gozo MC, Cho M, Sy M, Longmate JA, Lee PP: Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. The Journal of clinical investigation 2019, 129(10):4464–4476.
11.Chen Y, Peng C, Chen J, Chen D, Yang B, He B, Hu W, Zhang Y, Liu H, Dai L et al: WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Molecular cancer 2019, 18(1):127.
12.Zhang B, Horvath S: A general framework for weighted gene co-expression network analysis. Statistical applications in genetics and molecular biology 2005, 4:Article17.
13.Zhou YY, Chen LP, Zhang Y, Hu SK, Dong ZJ, Wu M, Chen QX, Zhuang ZZ, Du XJ: Integrated transcriptomic analysis reveals hub genes involved in diagnosis and prognosis of pancreatic cancer. Molecular medicine 2019, 25(1):47.
14.Wu D, Hu S, Hou Y, He Y, Liu S: Identification of potential novel biomarkers to differentiate malignant thyroid nodules with cytological indeterminate. BMC cancer 2020, 20(1):199.
15.Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003, 362(9381):362–369.
16.Shah AN, Metzger O, Bartlett CH, Liu Y, Huang X, Cristofanilli M: Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents. The oncologist 2020.
17.Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 2004, 10(16):5367–5374.
18.Saltarella I, Desantis V, Melaccio A, Solimando AG, Lamanuzzi A, Ria R, Storlazzi CT, Mariggio MA, Vacca A, Frassanito MA: Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells 2020, 9(1).
19.Nigro A, Ricciardi L, Salvato I, Sabbatino F, Vitale M, Crescenzi MA, Montico B, Triggiani M, Pepe S, Stellato C et al: Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC. Frontiers in immunology 2019, 10:3135.
20.Kulkoyluoglu-Cotul E, Arca A, Madak-Erdogan Z: Crosstalk between Estrogen Signaling and Breast Cancer Metabolism. Trends in endocrinology and metabolism: TEM 2019, 30(1):25–38.
21.Piperigkou Z, Karamanos NK: Estrogen receptor-mediated targeting of the extracellular matrix network in cancer. Seminars in cancer biology 2020, 62:116–124.
22.Ebright RY, Lee S, Wittner BS, Niederhoffer KL, Nicholson BT, Bardia A, Truesdell S, Wiley DF, Wesley B, Li S et al: Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. Science 2020.
23.Wang M, Hu Y, Stearns ME: RPS2: a novel therapeutic target in prostate cancer. Journal of experimental & clinical cancer research: CR 2009, 28:6.
24.Wang M, Hu Y, Amatangelo MD, Stearns ME: Role of ribosomal protein RPS2 in controlling let–7a expression in human prostate cancer. Molecular cancer research: MCR 2011, 9(1):36–50.
25.Wang RX, Xu XE, Huang L, Chen S, Shao ZM: eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer. Annals of translational medicine 2019, 7(23):783.
26.Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat B: Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PloS one 2012, 7(7):e41171.
27.Bayraktar R, Ivan C, Bayraktar E, Kanlikilicer P, Kabil NN, Kahraman N, Mokhlis HA, Karakas D, Rodriguez-Aguayo C, Arslan A et al: Dual Suppressive Effect of miR–34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. Clinical cancer research: an official journal of the American Association for Cancer Research 2018, 24(17):4225–4241.
28.Dong Z, Jiang H, Liang S, Wang Y, Jiang W, Zhu C: Ribosomal Protein L15 is involved in Colon Carcinogenesis. International journal of medical sciences 2019, 16(8):1132–1141.
29.He Z, Xu Q, Wang X, Wang J, Mu X, Cai Y, Qian Y, Shao W, Shao Z: RPLP1 promotes tumor metastasis and is associated with a poor prognosis in triple-negative breast cancer patients. Cancer cell international 2018, 18:170.